Amylyx Pharmaceuticals (AMLX) EPS (Basic) (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted EPS (Basic) of -$0.39 for Q2 2026, down 4.64% on a QoQ basis from -$0.37 in Q1 2026, and up 16.11% year-over-year from -$0.34 in Q2 2025.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) EPS (Basic) (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals has reported EPS (Basic) for 6 years, with the latest figure at -$0.39 in Q2 2026.
- On a quarterly basis, EPS (Basic) rose 16.11% year-over-year to -$0.39 in Q2 2026; TTM through Jun 2026 was -$1.09, a 21.77% increase from a year earlier, with the FY2025 full-year figure at -$1.21, up 65.49% from the prior year.
- EPS (Basic) was -$0.39 for Q2 2026 at Amylyx Pharmaceuticals, down from -$0.37 in the prior quarter.
- The five-year high for EPS (Basic) was $0.37 in Q4 2024, with the low at -$1.75 in Q1 2024.
- Average EPS (Basic) over 5 years is -$0.46, with a median of -$0.4 recorded in 2025.
- The largest YoY upside for EPS (Basic) was 458.47% in 2024 against a maximum downside of 7525.45% in 2024.
- Over 5 years, EPS (Basic) stood at -$0.75 in 2022, then soared by 108.95% to $0.07 in 2023, then surged by 458.47% to $0.37 in 2024, then plunged by 107.26% to -$0.03 in 2025, then plunged by 1335.71% to -$0.39 in 2026.
- The last three EPS (Basic) figures came in at -$0.39 (Q2 2026), -$0.37 (Q1 2026), and -$0.03 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | -0.40 |
| 10 | Amylyx Pharmaceuticals | 3.70 Bn | 3.70 Bn | - | -0.39 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.39 |
| Mar 31, 2026 | -0.37 |
| Dec 31, 2025 | -0.03 |
| Sep 30, 2025 | -0.37 |
| Jun 30, 2025 | -0.46 |
| Mar 31, 2025 | -0.42 |
| Dec 31, 2024 | 0.37 |
| Sep 30, 2024 | -1.07 |
| Jun 30, 2024 | -1.07 |
| Mar 31, 2024 | -1.75 |
| Dec 31, 2023 | 0.07 |
| Sep 30, 2023 | 0.31 |
| Jun 30, 2023 | 0.33 |
| Mar 31, 2023 | 0.02 |
| Dec 31, 2022 | -0.75 |
| Sep 30, 2022 | -0.92 |
| Jun 30, 2022 | -0.93 |
| Mar 31, 2022 | -0.93 |
| Dec 31, 2021 | -4.30 |
| Sep 30, 2021 | -3.42 |